TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma

Table 1 Histopathological and molecular characteristics of the cell models

	Histology	BRAF V600E	TERT prom. mutation	TERT mRNA expression	CDKN2A expression	Additional genetic aberrations	Stable cell line
BTL1333	GBM^*	wt	wt	neg	pos	TP53(D228V)*	yes
BTL53	GBM	wt	wt	pos	pos	TP53(V173M) RB1 deletion	yes
BTL2176	GBM	wt	C228T	pos	neg	PIK3CA(N1044K)	yes
NMC-G1	GBM	pos	C228T (homozygous)	pos	neg	–	yes
DBTRG-05MG	GBM	pos	C228T	pos	neg	POT1(G40)*	yes
AM38	GBM	pos	C250T	pos	neg	ALK(S737 L)	yes
VBT92	aPXA⁺	pos	C228T	pos	neg	–	yes
VBT125	GS^o	pos	C228T	pos	neg	–	yes
BTL1304	GS	pos	C228T	pos	neg	PTEN(K266E)	yes
BTL2231	PXA^#	pos	wt	neg	neg	–	no
VBT150	PXA	pos	wt	neg	pos	n.a.	no
VBT172	aPXA	pos	wt	neg	pos	n.a	no

^* GBM = glioblastoma multiforme
⁺aPXA = anaplastic pleomorphic xanthoastrocytoma
^oGS = gliosarcoma
^#PXA = pleomorphic xanthoastrocytoma
pos positive, neg negative, wt wild-type, mut mutated, n.a. not analyzed

ISSN: 2051-5960